Nemaura Medical to Participate in Fireside Chat Hosted by EF Hutton
March 21 2023 - 8:00AM
Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the
“Company”), a medical technology company focused on developing and
commercializing non-invasive wearable sensors and supporting
personalized lifestyle and weight reduction programs, today
announces that CEO Dr. Faz Chowdhury will participate in a fireside
chat on March 29, 2023 at 10am ET and being hosted by EF Hutton
research analyst Constantine Davides.
Discussion topics will likely include Nemaura’s
unique glucose monitoring device and its complementary digital
health solutions, the Company’s commercial strategy and channel
partnerships, early Miboko patient data from its UK pilot program,
and the regulatory progress with the FDA.
Investors can register for this fireside chat by
clicking this link.
About Nemaura
Medical, Inc.
Nemaura Medical Inc. is a medical technology
company developing and commercialising non-invasive wearable
diagnostic devices. The Company is currently also commercialising
sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class
IIb medical device, as a non-invasive and flexible continuous
glucose monitor (CGM) providing actionable insights derived from
real time glucose measurements and daily glucose trend data, which
may help people with diabetes and prediabetes to better manage,
reverse, and prevent the onset of diabetes. Nemaura has submitted a
PMA (Premarket Approval Application) for sugarBEAT® to the US
FDA. proBEAT™ combines non-invasive glucose data processed
using artificial intelligence under a digital healthcare
subscription service as part of its BEAT® diabetes
program.
The Company sits at the intersection of the
global Type 2 diabetes market that is expected to reach nearly $59
billion by 2025, the $50+ billion pre-diabetic market, and the
wearable health-tech sector for weight loss and wellness
applications that is estimated to reach $60 billion by 2023.
For more information, please
visit www.NemauraMedical.com.
Cautionary Statement Regarding
Forward-Looking Statements:
The statements in this press release that are
not historical facts may constitute forward-looking statements that
are based on current expectations and are subject to risks and
uncertainties that could cause actual future results to differ
materially from those expressed or implied by such statements.
Those risks and uncertainties include, but are not limited to, the
launch of proBEAT™ in the U.S., risks related to regulatory
status and the failure of future development and preliminary
marketing efforts, Nemaura’s ability to secure additional
commercial partnering arrangements, risks and uncertainties
relating to Nemaura’s and its partners’ ability to develop, market
and sell proBEAT™, the availability of substantial additional
equity or debt capital to support its research, development and
product commercialization activities, and the success of its
research, development, regulatory approval, marketing and
distribution plans and strategies, including those plans and
strategies related to both proBEAT™ digital health, and
sugarBEAT®. There can be no assurance that the Company will be able
to reach a part of or any of the global market for CGM with its
products/services. The U.S. Food and Drug Administration (the
“FDA”) reserves the right to re-evaluate its decision that
proBEAT™ qualifies as a general wellness product should it
become aware of any issues such as skin irritation or other adverse
events from the device, as well as any misuse impacting patient
safety, and any other reason as the FDA may see fit at its
discretion to determine the product does not fit the definition of
a general wellness product. These and other risks and uncertainties
are identified and described in more detail in Nemaura’s filings
with the United States Securities and Exchange Commission,
including, without limitation, its Annual Report on Form 10-K for
the most recently completed fiscal year, its Quarterly Reports on
Form 10-Q, and its Current Reports on Form 8-K. Nemaura undertakes
no obligation to publicly update or revise any forward-looking
statements.
Media Contacts
Jules AbrahamCORE IR+1 917-885-7378
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jul 2023 to Jul 2024